Biotech IV Monitor

DCPH — Deciphera Pharmaceuticals Inc.

Acquired by Ono Pharmaceutical · June 2024
Deciphera Pharmaceuticals Inc. was acquired by Ono Pharmaceutical in June 2024. DCPH no longer trades, so its trials are no longer stock catalysts and are left off the trial calendar. The records below are kept for reference; the programs now belong to Ono Pharmaceutical, and their dates may not have been updated since.

Clinical trial readout dates for Deciphera Pharmaceuticals Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is March 2027.

Next readoutMarch 2027in ~4 months
Upcoming readouts51 Phase 3

Upcoming readouts

Phase 1/2 Inlexisertib
GIST · NCT05957367
March 2027
Ongoing
Phase 3 Ripretinib
GIST · NCT05734105
December 2027
Ongoing
Phase 1/2 DCC-3009
Gastrointestinal Stromal Tumor (GIST) · NCT06630234
May 2028
Recruiting
Phase 1/2 Vimseltinib
Advanced Malignant Neoplasm; Pigmented Villonodular Synovitis · NCT03069469
August 2028
Ongoing
Phase 2 Vimseltinib
Chronic Graft-Versus-Host Disease (cGVHD) · NCT06619561
October 2029
Recruiting

Companies working on similar indications

Discussion

No messages yet. If you follow DCPH, you can start the conversation.
Contact — questions or corrections about DCPH: dukeupt@gmail.com